Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATG Based Conditioning Regimen in HLA Related Allogeneic HSCT for Aggressive T-cell Tumors
NCT02938741Phase 4Unknown
- Sponsor
- Shanghai General Hospital
- Start
- Oct 2016
- Primary completion
- Dec 2021
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in lymphoblastic lymphoma (LL) and aggressive T-cell lymphoma (PTCL) comparing r-ATG Immunosuppressive agents with placebo (2 arms). Primary endpoint: Relapse Free Survival at 2 years. Status: unknown.
02
Drugs
antithymocyte globulin rabbit
03
Conditions
lymphoblastic lymphoma (LL)aggressive T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT02938741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02938741.